Because the restoration of wild-type p53 function in osteosarcoma cells has not succeeded clinically owing to the complexity of p53 signalling1, identification of druggable p53 downstream molecules or pathways could be key to attacking p53-deficient tumours such as osteosarcoma. The gene discussed is TP53; the disease is osteosarcoma.